1-3 of 3
Chantal Guillemette
Close
Sort by
Journal Articles

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Christoph Kornauth, Charles Herbaux, MD MSc, Bernd Boidol, PhD, Chantal Guillemette, Patrick Caron, Stéphanie Poulain, MD PhD, Olivier Tournilhac, Marius E Mayerhoefer, Ulrich Jaeger, MD, Stefan Kubicek, Matthew S. Davids, MD, Philipp Bernhard Staber, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3965.
https://doi.org/10.1182/blood-2019-124392
Published: 2019
Journal Articles

Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia

Clinical Trials & Observations
Michaela Gruber, Judith Bellemare, Gregor Hoermann, Andreas Gleiss, Edit Porpaczy, Martin Bilban, Trang Le, Sonja Zehetmayer, Christine Mannhalter, Alexander Gaiger, Medhat Shehata, Karin Fleiss, Cathrin Skrabs, Éric Lévesque, Katrina Vanura, Chantal Guillemette, Ulrich Jaeger
Journal: Blood
Blood (2013) 121 (7): 1175–1183.
https://doi.org/10.1182/blood-2012-08-447359
Published: 2013
Includes: Supplemental data
Journal Articles

UGT1A8 and UGT1A9 as Molecular Determinants of Mycophenolate Mofetil (MMF) Pharmacokinetics.

Eric Levesque, MD, PhD, Robert Delage, MD,MSC, Marie-Odile Benoit Biancamano, MSC, Felix Couture, MD, Chantal Guillemette, PhD
Journal: Blood
Blood (2006) 108 (11): 3191.
https://doi.org/10.1182/blood.V108.11.3191.3191
Published: 2006